Recombinant Cynomolgus / Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, His tag, 100µg

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Source
Recombinant Cynomolgus / Rhesus macaque OX40, His Tag (OX0-C5220) is expressed from human 293 cells (HEK293). It contains AA Lys 28 - Ala 214 (Accession # XP_001090870.1). In the region Lys 28 - Ala 214, the AA sequence of Cynomolgus and Rhesus macaque OX40 are homologus.
Predicted N-terminus: Lys 28

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.1 kDa. The protein migrates as 33-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors"
Goldman, Piha-Paul, Curti et al
Clin Cancer Res (2022)
(2) "First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors"
Kim, Burris, de Miguel Luken et al
Clin Cancer Res (2022)
(3) "High soluble OX40 levels correlate with metastatic gastric cancer"
Lima, Martins, Dos Santos et al
J Surg Oncol (2022) 126 (1), 139-143
Showing 1-3 of 1816 papers.